Showing results (351-360 of 654) with videos related to

Sort By:
Pageof 66
Molecular Cancer Therapeutics|September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsPrasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Nature Methods|April 17, 2019
Integrated transcriptomic-genomic tool Texomer profiles cancer tissuesFang Wang, Shaojun Zhang, Tae-Beom Kim, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Oncotarget|May 6, 2016
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experienceMing-Mo Hou, Zhijie Wang, Filip Janku, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2016
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancersMuhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, et al.
International Journal of Radiation Oncology, Biology, Physics|August 19, 2008
Ten-year recurrence rates in young women with breast cancer by locoregional treatment approachBeth M Beadle, Wendy A Woodward, Susan L Tucker, et al.
Database : the Journal of Biological Databases and Curation|April 11, 2015
Using Ontology Fingerprints to disambiguate gene name entities in the biomedical literatureGuocai Chen, Jieyi Zhao, Trevor Cohen, et al.
Annals of Surgical Oncology|October 8, 2011
Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancerJamie L Wagner, Regina Fearmonti, Kelly K Hunt, et al.
The Oncologist|March 26, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignanciesJibran Ahmed, Anne Knisely, Carlos Torrado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional AnalysisSunyoung S Lee, Dong Hyun Seo, Taek Chung, et al.
Pageof 66